Phase II Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor.

Trial Profile

Phase II Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Jun 2017

At a glance

  • Drugs Sunitinib (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Advanced breast cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Most Recent Events

    • 02 Jun 2017 Results (n=12) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 21 Jun 2016 Planned End Date changed from 1 Dec 2016 to 1 Dec 2017.
    • 21 Jun 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top